Rigerna
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $28M
Overview
A clinical-stage Chinese biotech developing siRNA drugs with proprietary delivery platforms for liver and non-liver tissues.
Genetic DiseasesRare DiseasesChronic Diseases
Technology Platform
Proprietary platforms for siRNA drug development: RIHOST® (intelligent design/screening), RICMO® (chemical modification), and LICOD® (in vivo delivery), with a focus on enabling delivery to non-liver tissues.
Opportunities
The global siRNA market is expanding rapidly, and Rigerna's proprietary non-liver delivery technology could unlock high-value targets in central nervous system, ocular, renal, and muscular diseases, representing a significant addressable market.
Risk Factors
As an early-stage company, Rigerna faces high technical risk in validating its delivery platforms in humans, intense competition from established global players, and execution risk in advancing its first candidate into the clinic.
Competitive Landscape
Competes with Alnylam, Ionis, and Arrowhead globally, and with Suzhou Ribo Life Science and Sirnaomics in China; differentiation is claimed through its proprietary non-liver delivery platforms (RIHOST®/LICOD®).